

RECEIVED
CENTRAL FAX CENTER

NIKOLAI & MERSEREAU, P.A.
900 SECOND AVENUE SOUTH, SUITE 820
MINNEAPOLIS, MN, U.S.A. 554023325
Telephone: (612) 339-7461 Facsimile: (612) 349-6556

FACSIMILE TRANSMISSION**TO:**

Name: Examiner Jane J. Zara
Firm: USPTO
City: State:

Fax No.: 703-872-9306**Country:** USA**FROM:**

Name: C. G. Mersereau
NIKOLAI & MERSEREAU, P.A., 900 Second Ave. S., #820, Minneapolis, MN 55402, U.S.A.

Fax No.: (612) 349-6556**DATE:** June 21, 2005 **Time:** 10:40 a.m. **TOTAL PAGES incl. cover sheet:** 16

If you do not receive all pages, please call the Telecopier Operator at (612) 339-7461 ASAP.

This fax transmission is confidential and may be privileged and only is intended for use of the addressee. If you are not the addressee (or a person responsible for delivering this transmission to the addressee), do not use this transmission in any way, but promptly contact the telecopier operator by telephone at (612) 339-7461.

Telecopier Operator:

Barbara L. Davis

MESSAGE:



INTERNATIONAL CENTRE
900 SECOND AVENUE SOUTH, SUITE 820
MINNEAPOLIS, MINNESOTA 55402-3813
TELEPHONE 612 339-7461
FACSIMILE 612 349-6556

RECEIVED
CENTRAL FAX CENTER
JUN 21 2005

June 21, 2005

PATENT APPLICATION

Our Docket No. 20010529.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Lakjaya Buluwela et al
S.N. : 10/019,520 : Art Unit 1635
Filed : June 10, 2002 : Examiner Jane J. Zara
For : CONTROL OF GENE EXPRESSION

MAIL STOP NON-FEE AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a Response to Election/Restriction Requirement in response to an Office Action mailed June 2, 2005 in the above-identified patent application.

The Commissioner is hereby authorized to charge any fees listed in 37 CFR 1.16 and 1.17 which may be required by this paper or credit any overpayment to Deposit Account No. 08-1265.

No additional fee is required.

Yours very truly,

NIKOLAI & MERSEREAU, P.A.

A handwritten signature in cursive script, appearing to read "C. G. Mersereau".

C. G. Mersereau

CGM/bld

Enclosure

Our Docket No. 20010529.ORI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App : Lakjaya Buluwela et al : June 21, 2005
S.N. : 10/019,520 : Art Unit 1635
Filed : June 10, 2002 : Examiner Jane J. Zara
For : CONTROL OF GENE EXPRESSION

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to an Official Office Action dated June 2, 2005, which was in the form of an election/restriction requirement and carried a shortened-statutory period for response of one month so that a reply is due by July 2, 2005. It is noted that the present Action replaces an earlier restriction requirement dated March 22, 2005 which has been vacated in favor of the present restriction requirement. The present election/restriction requirement restricts examination to one of the following inventions as required under 35 USC § 121.

- I. Claims 53-88, drawn to compositions and methods comprising the administration of a polypeptide.
- II. Claims 53-106, drawn to compositions and methods comprising the administration of a polynucleotide.

Additionally, applicants have been required to elect a single nucleic acid binding portion and a single chromatin inactivation portion (e.g. including where appropriate electing a single facilitating recruitment of or component of HDAC from claim 62) from the corresponding elected group.

To comply with the election/restriction requirement, applicants hereby elect Group I containing claims 53-88 as drawn to compositions and methods comprising the administration of a polypeptide. In addition, to comply with the species election requirement, applicants select a nucleic acid binding portion species a "all or a DNA-binding portion of androgen receptor (AR) and the applicants select a chromatin inactivation portion as all of PLZF". See claim 75.

Applicants further traverse the restriction requirement inasmuch as unity of invention in the application has been upheld elsewhere and it is believed while certain differences may exist between portions of the claims of Group I and Group II, that they are really part of one generic invention and should be examined together.

Withdrawal of the restriction requirement and early examination and allowance of the claims is respectfully requested.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



C. G. Mersereau
Attorney Registration No. 26,205
Attorney for Applicants
900 Second Avenue South
Suite 820 International Centre
Minneapolis, MN 55402
Telephone: (612) 339-7461